MaxCyte, Inc. MaxCyte, Inc.

MaxCyte, Inc.

MXCT

Rank in Stocks #18614
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes... MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Share Price
$1.19
Last synced: 2026-11-13
Market Cap
$123.21M
Change (1 day)
0.00%
Change (1 year)
-28.74%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
P/E ratio for MaxCyte, Inc. (MXCT)
P/E ratio as of November 2026 TTM: -4.50
According to MaxCyte, Inc.'s latest financial reports and stock price, its current price-to-earnings ratio (TTM) is -4.50. At the end of 2025 the company had a P/E ratio of -3.69.
P/E ratio history for MaxCyte, Inc. from 2012 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -4.50 22.02%
2025 -3.69 -65.26%
2024 -10.62 -16.99%
2023 -12.80 -45.67%
2022 -23.56 -51.32%
2021 -48.39 -51.58%
2020 -99.94 34.41%
2019 -74.35 -24.21%
2018 -98.10 17.65%
2017 -83.39 -51.04%
2016 -170.31 -66.69%
2015 -511.24 4,691.02%
2014 -10.67 -98.62%
2013 -771.24 107.51%
2012 -371.65 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
-8.15 80.92%
US
34.39 -863.87%
US
-31.59 601.70%
US
-25.99 477.13%
AU
25.67 -670.15%
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.

Questions about MaxCyte, Inc.'s P/E ratio

What is MaxCyte, Inc.'s P/E ratio?

MaxCyte, Inc.'s P/E ratio is -4.50, as of Nov 2026.

What was MaxCyte, Inc.'s P/E ratio in 2025?

In 2025, MaxCyte, Inc.'s P/E ratio was -3.69, compared with -10.62 in 2024.

How has MaxCyte, Inc.'s P/E ratio changed since 2020?

From 2020 to 2025, MaxCyte, Inc.'s P/E ratio was highest in 2025 (-3.69) and lowest in 2020 (-99.94).

How does MaxCyte, Inc.'s P/E ratio compare with similar companies?

MaxCyte, Inc.'s P/E ratio (-4.50) is higher than that of 3 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 34.39.